What is Invivyd, Inc. (IVVD) stock price today?

Invivyd, Inc. (IVVD) is currently trading at $0.72, up 2.97% today.

What is IVVD P/E ratio?

Invivyd, Inc.'s P/E ratio is -2.08. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IVVD return on equity (ROE)?

Invivyd, Inc.'s return on equity (ROE) is -59.73%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Invivyd, Inc.'s market cap?

Invivyd, Inc. has a market capitalization of $212.47M.

NASDAQ · Biotechnology

Invivyd, Inc. (IVVD) Stock

$0.72 +2.97% NASDAQ: IVVD Healthcare

Valuation

Metric	Value
Price	$0.72
Market Cap	$212.47M
P/E Ratio	-2.08
P/B Ratio	1.45
P/S Ratio	4.15
EPS (TTM)	$-0.30
52-Week High	$3.07
52-Week Low	$0.53
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-59.73%
ROA	-49.04%
ROCE	-59.90%
Gross Margin	-105.66%
Operating Margin	-105.66%
Net Margin	-183.90%
Debt/Equity	0.05
Current Ratio	7.26

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$25.0M	$53.0M
Operating Profit	$-227.0M	$-248.0M	$-213.0M	$-177.0M	$-56.0M
Net Profit	$-227.0M	$-241.0M	$-199.0M	$-170.0M	$-52.0M
EPS	$-2.11	$-2.17	$-1.81	$-1.43	$-0.30
Op Margin	—	—	—	-696.8%	-104.0%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$620.0M	$383.0M	$229.0M	$130.0M	$277.0M
Total Liabilities	$62.0M	$27.0M	$52.0M	$62.0M	$35.0M
Cash	$542.0M	$92.0M	$201.0M	$69.0M	$227.0M
Borrowings	$0	$4.0M	$2.0M	$1.0M	$2.0M

Latest News

IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval Stocktwits · Jul 6, 2026 Invivyd Gets FDA Notice of Pemgarda COVID-19 Emergency Use Authorization Termination MT Newswires · Jul 6, 2026 Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA GlobeNewswire · Jul 6, 2026 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer GlobeNewswire · Jun 29, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-185.0M	$-220.0M	$-173.0M	$-170.0M	$-58.0M
Investing Cash Flow	$-51.0M	$-232.0M	$280.0M	$0	$0
Financing Cash Flow	$-3.0M	$0	$0	$-1.0M	$0
Net Cash Flow	$427.0M	$-450.0M	$109.0M	$-131.0M	$157.0M
Free Cash Flow	$-185.0M	$-222.0M	$-174.0M	$-171.0M	$-58.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.03
EV / EBITDA	-0.84
FCF Yield	-45.28%
Quick Ratio	5.86
Interest Coverage	0.00
Return 1Y	10.18%
Return 3Y	-42.37%
Return 5Y	—

Ownership

Insiders Held7.07%

Institutions Held83.97%

Institutions Float Held90.36%

Institutional Holder	Shares	Report Date
Janus Henderson Group PLC	33,094,330	2026-03-31
Perceptive Advisors Llc	20,859,303	2026-03-31
BVF Inc.	19,525,000	2026-03-31
Maverick Capital Ltd.	18,970,913	2026-03-31
Saturn V Capital Management LP	10,949,084	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$336.64	-1.11%	38.93	$4.94T	0.32%
MSFTMicrosoft Corporation	$535.07	+2.38%	28.68	$3.97T	0.76%
GOOGLAlphabet Inc.	$351.66	+0.97%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$262.43	+3.29%	19.82	$2.82T	0.00%
METAMeta Platforms, Inc.	$718.67	-0.31%	27.93	$1.83T	0.28%

About Invivyd, Inc.

Invivyd, Inc. is led by CEO William E. Duke Jr., employs 99 people, headquartered in US, publicly traded since 2021.

Invivyd, Inc. (IVVD) stock trades at $0.72 with a market capitalization of $212.47M. The stock is valued at a price-to-earnings (P/E) ratio of -2.08, price-to-book of 1.45, price-to-sales of 4.15. Over the past 52 weeks the stock has ranged between $0.53 and $3.07, and currently trades 76.5% below its 52-week high.

On profitability, Invivyd, Inc. generates a return on equity (ROE) of -59.73%, return on capital employed of -59.90%, an operating margin of -105.66%, a net profit margin of -183.90%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides